Nuclear Antigen Antikörper
Kurzübersicht für Nuclear Antigen Antikörper (ABIN6297660)
Target
Alle Nuclear Antigen (IPO-38) Antikörper anzeigenReaktivität
Wirt
Klonalität
Konjugat
Applikation
- 
    - 
                                            Verwendungszweck
- Mouse anti-Human/Mouse/Rat IPO-38 Antibody (Proliferation Marker) [Sodium Azide Free]
- 
                                            Spezifität
- Nuclear
- 
                                            Aufreinigung
- Spleen cells from a patient with hairy cell leukemia were used as the immunogen for the IPO-38 antibody.
- 
                                            Immunogen
- Spleen cells from a patient with hairy cell leukemia were used as the immunogen for the IPO-38 antibody.
 
- 
                                            
- 
    
- 
    - 
                                            Applikationshinweise
- 
                        Flow Cytometry: 0.5-1 μg/million cells in 0.1ml
 Immunofluorescence: 0.5-1 μg/mL
 Immunohistochemistry (FFPE): 0.5-1 μg/mL for 30 min at RT (1)
 Prediluted format: incubate for 30 min at RT (2)
- 
                                            Beschränkungen
- Nur für Forschungszwecke einsetzbar
 
- 
                                            
- 
    - 
                                            Buffer
- In 1X PBS, BSA free, sodium azide free
- 
                                            Konservierungsmittel
- Azide free
- 
                                            Lagerung
- 4 °C,-20 °C
- 
                                            Informationen zur Lagerung
- 2-8°C. The azide-free format should be aliquoted and stored at -20°C or colder.
 
- 
                                            
- 
    - Nuclear Antigen (IPO-38)
- 
                                            Andere Bezeichnung
- IPO38
- 
                                            Hintergrund
- 
                        Target Description: Recognizes a protein of 14-16 kDa, which is a novel nuclear antigen of proliferating cells. IPO38 antigen is present in the nuclei of proliferating cells such as Hodgkin s disease and non-Hodgkin s lymphomas, different forms of leukemias, breast and colorectal carcinomas, and PHA-stimulated lymphocytes. It is not expressed in the cells of non-stimulated lymphocytes and granulocytes. IPO38 may be a useful marker of cell proliferation during monitoring of tumor progression. 
 Target
- 
                    
 
                                     
                                     
                                    